UK's BBI and NIST in partnership for gold nanoparticles
This article was originally published in Clinica
Cardiff, UK-based BBI has been chosen by the US National Institute of Standards and Technology (NIST) to provide gold nanoparticles to make nanoscale reference materials for the evaluation and qualification of methodology and instrument performance. The resulting materials will help diagnostic firms make sure that equipment is performing with the required QC parameters for the measurement and characterisation of quality nanoparticles. The gold nanoparticles are used in membrane-based rapid assays due to their stability and ultra-sensitivity. BBI is currently in the process of being acquired by Inverness Medical Innovations (see Clinica No 1286, p 3).
You may also be interested in...
Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.
Transparency On COVID Vaccine Clinical Holds Needed, Sharfstein Says; US FDA Advisory Cmtes Offer Venue
Former acting Commissioner Josh Sharfstein argues that while agency officials have done a commendable job in overall communication on COVID vaccine development, more information is needed on the clinical holds.
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.